Literature DB >> 28488978

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report.

Ian Chong1, Alice Chao2.   

Abstract

INTRODUCTION: One of the most dangerous dermatologic emergencies is Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN). Although a rare disease, it can often lead to significant mortality. CASE
PRESENTATION: In this case report, we present a 77-year-old man who developed a sloughing rash that was secondary to a nonsteroidal anti-inflammatory drug. In addition to the recommended supportive care, the patient was treated with etanercept, a new, less commonly used intervention. DISCUSSION: We provide a brief review of SJS/TEN. Nonsteroidal anti-inflammatory drugs are a rare cause of SJS/TEN, and additionally, the use of biologics is a novel treatment modality for SJS/TEN.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28488978      PMCID: PMC5424646          DOI: 10.7812/TPP/16-060

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  30 in total

Review 1.  Toxic epidermal necrolysis (Lyell syndrome).

Authors:  J C Roujeau; O Chosidow; P Saiag; J C Guillaume
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

2.  Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.

Authors:  E Schöpf; A Stühmer; B Rzany; N Victor; R Zentgraf; J F Kapp
Journal:  Arch Dermatol       Date:  1991-06

3.  A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin.

Authors:  A T Mansur; I A Aydingöz
Journal:  Photodermatol Photoimmunol Photomed       Date:  2005-04       Impact factor: 3.135

4.  Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: definition of a new model based on translational research.

Authors:  Afshin Sadighha
Journal:  Int J Dermatol       Date:  2009-08       Impact factor: 2.736

5.  Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.

Authors:  P H Halebian; V J Corder; M R Madden; J L Finklestein; G T Shires
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

6.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Authors:  I Garcia-Doval; L LeCleach; H Bocquet; X L Otero; J C Roujeau
Journal:  Arch Dermatol       Date:  2000-03

7.  Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  P Wolkenstein; O Chosidow; M L Fléchet; O Robbiola; M Paul; L Dumé; J Revuz; J C Roujeau
Journal:  Contact Dermatitis       Date:  1996-10       Impact factor: 6.600

Review 8.  Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions.

Authors:  W Ting; M S Stone; D Racila; R H Scofield; R D Sontheimer
Journal:  Lupus       Date:  2004       Impact factor: 2.911

9.  Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre.

Authors:  B Gerdts; A F P M Vloemans; R W Kreis
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-07       Impact factor: 6.166

Review 10.  An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods.

Authors:  J P Kelly; A Auquier; B Rzany; L Naldi; S Bastuji-Garin; O Correia; S Shapiro; D W Kaufman
Journal:  J Clin Epidemiol       Date:  1995-09       Impact factor: 6.437

View more
  2 in total

Review 1.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

2.  Survey of Nonprescription Medication and Antibiotic Use in Patients with Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Overlap Syndrome.

Authors:  Katherine J Sullivan; Meghan N Jeffres; Robert P Dellavalle; Robert Valuck; Heather D Anderson
Journal:  Antibiotics (Basel)       Date:  2018-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.